Drugs Containing Excipient (Inactive Ingredient) CARBOMER HOMOPOLYMER TYPE C

« Back to Dashboard

Branded drugs containing CARBOMER HOMOPOLYMER TYPE C excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ACZONE	dapsone	0023-3670	CARBOMER HOMOPOLYMER TYPE C
Viatris Specialty LLC	ELESTRIN	estradiol	0037-4801	CARBOMER HOMOPOLYMER TYPE C
AbbVie Inc	ANDROGEL	testosterone	0051-8462	CARBOMER HOMOPOLYMER TYPE C

Generic drugs containing CARBOMER HOMOPOLYMER TYPE C excipient

Company	Ingredient	NDC	Excipient
Allergan Inc	dapsone	0023-3670	CARBOMER HOMOPOLYMER TYPE C
Viatris Specialty LLC	estradiol	0037-4801	CARBOMER HOMOPOLYMER TYPE C
AbbVie Inc	testosterone	0051-8462	CARBOMER HOMOPOLYMER TYPE C

Carbomer Homopolymer Type C Market Dynamics, Financial Trajectory, Regulatory Status, and Competitive Landscape

Last updated: November 8, 2026

Carbomer Homopolymer Type C is a pharmaceutical-grade crosslinked polyacrylic acid excipient used primarily as a rheology modifier, suspending agent, bioadhesive, and controlled-release polymer. It is a specialty excipient rather than a separately reported public-market category. Manufacturers generally disclose carbomer revenue within broader excipient, pharmaceutical ingredients, or specialty chemicals segments.

The market outlook is stable to moderately positive. Demand is tied to topical pharmaceuticals, ophthalmic products, oral liquids, controlled-release tablets, veterinary medicines, and consumer-health formulations. Pricing power is strongest for compendial grades with regulatory files, validated supply chains, and demonstrated performance in commercial formulations.

What is Carbomer Homopolymer Type C?

Carbomer Homopolymer Type C is a pharmacopeial category covering crosslinked polyacrylic acid polymers. The material is typically supplied as a dry, white, highly swelling powder that develops viscosity after neutralization or dispersion in an appropriate formulation system.

The excipient is identified by compendial and supplier specifications rather than by a single universal commercial product. Commercial designations may include carbomer, Carbopol, pharmaceutical carbomer, or supplier-specific grades. Carbopol is a registered trademark associated with Lubrizol Advanced Materials.

Typical functions include:

• Thickening and viscosity control
• Suspension stabilization
• Emulsion stabilization
• Mucoadhesion
• Bioadhesion
• Controlled drug release
• Gel formation in topical, ophthalmic, and oral formulations

The commercial performance of a Type C material depends on particle size, crosslink density, neutralization behavior, viscosity profile, residual solvent and monomer levels, microbial quality, and compatibility with active pharmaceutical ingredients.

How large is the Carbomer Homopolymer Type C market?

No authoritative source reports a standalone global market size for Carbomer Homopolymer Type C. Public market studies usually combine carbomers with acrylic polymers, rheology modifiers, pharmaceutical excipients, or specialty polymers. Supplier financial statements also do not isolate Type C revenue.

This reporting structure limits precise market-size and growth-rate calculations. The relevant economic indicators are instead:

Market indicator	Effect on Type C demand
Topical drug development	Positive
Ophthalmic formulation growth	Positive
Oral controlled-release products	Positive
Generic drug manufacturing	Positive, but price-sensitive
Consumer skincare demand	Positive, though not all demand is pharmaceutical-grade
Supplier qualification requirements	Supports incumbent suppliers
Acrylic acid and energy costs	Creates margin volatility
Availability of alternative polymers	Limits pricing power
Regulatory changes affecting excipients	Raises documentation costs

Pharmaceutical demand is more defensible than general personal-care demand because switching suppliers can require formulation work, stability studies, process validation, and regulatory documentation.

What are the main applications of Carbomer Homopolymer Type C?

Topical pharmaceutical gels

Carbomer is widely used in dermatological gels, creams, lotions, and transdermal formulations. It produces high viscosity at low concentrations and can create clear or translucent gels after neutralization.

The main commercial advantages are low use concentration, strong thickening efficiency, and compatibility with a broad range of topical actives. Formulation risks include sensitivity to electrolytes, pH, surfactants, preservatives, and certain cationic ingredients.

Ophthalmic products

Carbomer polymers are used in artificial tears, ocular gels, and other ophthalmic products requiring prolonged residence time. Ophthalmic applications impose tighter controls on microbial quality, particulate matter, endotoxins where applicable, extractables, and lot-to-lot viscosity.

Once an ophthalmic product is commercialized, supplier substitution can be difficult because changes may affect drop size, residence time, visual clarity, preservative performance, and patient tolerability.

Oral controlled-release formulations

Carbomer can function as a hydrophilic matrix former. Upon hydration, the polymer swells and creates a diffusion barrier that can slow active-ingredient release.

Its use in modified-release tablets is formulation-specific. The commercial value comes from its functional performance in the finished dosage form, not simply from the polymer’s identity. A change in grade may alter dissolution profiles and trigger additional regulatory work.

Oral liquids and suspensions

Carbomer improves suspension stability and viscosity in oral liquids. It can help prevent sedimentation and improve dose uniformity, although excessive viscosity can affect pourability, syringeability, and patient acceptance.

Veterinary and consumer-health formulations

Veterinary gels, oral suspensions, wound-care products, and nonprescription topical products create secondary demand. These applications often have shorter qualification cycles than prescription products but more price competition.

Which companies supply Carbomer Homopolymer Type C?

The market has a small number of globally recognized pharmaceutical-grade suppliers and a larger group of regional producers. The principal competitive differentiator is not basic polymer chemistry. It is the combination of compendial compliance, quality systems, regulatory support, supply continuity, and formulation data.

Supplier or supplier group	Competitive position
Lubrizol Advanced Materials	Major branded carbomer supplier; Carbopol pharmaceutical grades and technical support
Ashland	Broad pharmaceutical excipient portfolio and formulation-support capabilities; product availability depends on grade and market
BASF and other specialty-chemical suppliers	Compete in adjacent formulation polymers and rheology modifiers
Chinese and Indian manufacturers	Increasing price competition, regional supply, and contract-manufacturing support
Regional distributors	Provide inventory, importation, and local regulatory support

The supplier landscape varies by country. A manufacturer may qualify one global supplier and one regional backup supplier, but dual sourcing is constrained when the alternate grade has different viscosity, particle size, neutralization behavior, or release performance.

How strong is the patent estate for Carbomer Homopolymer Type C?

The core composition is a mature polymer technology with limited protection from new composition-of-matter patents. Older patents covering crosslinked polyacrylic acid polymers and their use have generally expired or have limited remaining commercial relevance.

Current competitive protection is more likely to arise from:

• Grade-specific manufacturing processes
• Crosslinking and particle-size controls
• Low-residual-monomer processes
• Purification methods
• Pharmaceutical formulations
• Controlled-release dosage forms
• Ophthalmic delivery systems
• Proprietary neutralization or processing methods
• Supplier quality and regulatory documentation

These protections normally cover a particular drug product or process rather than Carbomer Homopolymer Type C as a bulk excipient.

Manufacturing and intellectual-property barriers

The principal barrier to entry is qualification risk. A new supplier must demonstrate compliance with the applicable pharmacopeial monograph and customer-specific specifications. Drug manufacturers may require:

• Multiple commercial-scale batches
• Stability data
• Impurity profiles
• Residual acrylic acid data
• Microbial and elemental impurity controls
• Change-control commitments
• Supply-chain traceability
• Audits and quality agreements
• Demonstrated performance in the finished dosage form

This creates a meaningful barrier even when the underlying polymer chemistry is no longer strongly patent-protected.

What is the FDA regulatory status of Carbomer Homopolymer Type C?

Carbomer is an excipient, not an FDA-approved active pharmaceutical ingredient. The FDA generally does not approve excipients through a standalone approval pathway comparable to a new drug application.

Drug manufacturers establish excipient suitability through the finished product’s regulatory submission. Relevant evidence may include compendial compliance, manufacturing controls, safety information, supplier qualification, and formulation-performance data.

FDA regulatory considerations include:

• Compliance with the applicable USP-NF monograph
• Conformance with the drug product’s approved specifications
• Control of residual acrylic acid and other impurities
• Microbial quality
• Container-closure compatibility
• Stability and extractables data
• Change-control assessment

Carbomer entries may appear in the FDA Inactive Ingredient Database for specific routes and dosage forms. An IID listing supports precedent but does not automatically authorize every grade, concentration, route, or product configuration. [1]

What is the Orange Book status of Carbomer Homopolymer Type C?

Carbomer Homopolymer Type C does not have an Orange Book listing because the Orange Book lists approved drug products and their patent and exclusivity information, not excipients as standalone commercial products. [2]

Consequently:

• There is no Orange Book patent listing for the excipient itself.
• There is no standalone FDA exclusivity period.
• There is no Paragraph IV certification directed at the excipient.
• Generic-drug litigation concerns the finished drug product, not the polymer as a commodity input.

A carbomer-containing drug may have formulation, method-of-use, or controlled-release patents. Those rights attach to the finished product and may affect generic entry even when the excipient itself is off-patent.

When does Carbomer Homopolymer Type C lose exclusivity?

The excipient has no single loss-of-exclusivity date. Core carbomer chemistry is mature, and generic manufacturers can use alternative suppliers if they meet the drug product’s specifications.

Exclusivity can still exist at the product level through:

• Drug formulation patents
• Controlled-release matrix patents
• Ophthalmic gel or delivery patents
• Method-of-treatment patents
• Manufacturing-process patents
• Regulatory exclusivity for the active drug

This distinction is important. A supplier’s commercial grade may have proprietary manufacturing know-how, but that is different from statutory exclusivity over the excipient.

What patent litigation and Paragraph IV risks affect carbomer products?

Carbomer itself is not a typical target of Paragraph IV litigation. Paragraph IV disputes arise when a generic applicant challenges listed patents for an approved drug product under the Hatch-Waxman framework. [3]

Carbomer-related litigation risk can arise indirectly when:

1. A branded drug uses carbomer in a patented formulation.
2. A generic applicant uses a different carbomer grade but claims equivalent performance.
3. A patent covers viscosity, release rate, gel formation, or residence time.
4. The brand argues that the generic infringes a formulation or process claim.
5. The generic argues that the patent is invalid, unenforceable, or not infringed.

The highest litigation exposure is in modified-release oral products and specialized ophthalmic formulations. Conventional topical products generally face lower patent barriers unless the formulation has a narrow delivery or therapeutic-use claim.

What is the competitive landscape versus alternative polymers?

Carbomer competes with cellulose derivatives, natural gums, polyvinyl alcohol, polyvinylpyrrolidone, poloxamers, xanthan gum, alginates, and other acrylic polymers.

Excipient class	Strength relative to carbomer	Main limitation
Carbomer	High viscosity at low concentration; strong gel formation	Electrolyte and pH sensitivity
Hydroxypropyl methylcellulose	Established oral controlled-release platform	May require higher use levels
Hydroxypropyl cellulose	Broad pharmaceutical use and processing flexibility	Different viscosity and release behavior
Xanthan gum	Strong suspension performance and natural origin	Batch variability and sensory effects
Poloxamers	Thermoresponsive and solubilizing properties	Lower thickening efficiency in some systems
Polyvinyl alcohol	Useful in ophthalmic and film-forming products	Different rheology and processing profile
Sodium alginate	Bioadhesive and gel-forming properties	Ion sensitivity and raw-material variability

Substitution is technically possible but rarely immediate. The replacement must match product performance, manufacturing behavior, stability, safety, and regulatory commitments.

What is the financial trajectory for Carbomer Homopolymer Type C?

The financial trajectory is likely to be characterized by steady volume growth, moderate pricing pressure, and margin separation between pharmaceutical grades and commodity grades.

Revenue drivers

Demand should benefit from:

• Growth in topical and dermatological generics
• More ophthalmic lubricants and ocular gels
• Expansion of oral controlled-release products
• Increased use of ready-to-use pharmaceutical excipient systems
• Growth in emerging-market pharmaceutical production
• Continued consumer-health and personal-care demand

Margin pressures

Profitability can be affected by:

• Acrylic acid costs
• Energy and transportation expenses
• Environmental and wastewater controls
• Capacity utilization
• Regional competition from lower-cost suppliers
• Customer pressure for dual sourcing
• Validation costs for new grades
• Inventory requirements for regulated markets

Pharmaceutical-grade carbomer generally commands a premium over industrial and personal-care grades. The premium reflects quality documentation, testing, change control, and customer qualification rather than a fundamentally different polymer backbone.

Public-company revenue exposure

Public suppliers generally report carbomer within broader business units. Lubrizol is part of Berkshire Hathaway and does not provide a public, standalone Carbopol revenue line. Ashland reports pharmaceutical and specialty ingredients within broader segment reporting. Other suppliers similarly group carbomer with specialty polymers, pharmaceutical excipients, or performance materials.

As a result, Carbomer Homopolymer Type C should be analyzed as a product-line and supply-chain exposure rather than as an independently valued public-company segment.

What generic launch risks exist for carbomer-containing drugs?

Generic entry risk depends on the finished dosage form.

Dosage form	Generic entry risk	Reason
Conventional topical gel	High to moderate	Multiple polymers and formulation routes may be available
Oral solution or suspension	Moderate	Viscosity and dose-uniformity matching can be manageable
Modified-release tablet	Moderate to low	Release performance and formulation patents can restrict substitution
Ophthalmic gel	Moderate to low	Sterility, drop performance, residence time, and tolerability raise complexity
Complex bioadhesive system	Low to moderate	Functional equivalence can be difficult to demonstrate

The excipient itself rarely determines market exclusivity. It affects development cost, formulation similarity, and manufacturing risk.

What licensing deals involve Carbomer Homopolymer Type C?

Public licensing transactions specifically covering Carbomer Homopolymer Type C are uncommon. Commercial arrangements typically take the form of:

• Distribution agreements
• Regional supply contracts
• Technical-service agreements
• Contract-manufacturing relationships
• Excipient co-development programs
• Formulation partnerships

These arrangements are usually private and do not generate the public disclosure associated with drug licensing transactions. The strategic value lies in securing supply, regulatory support, and preferred access to validated grades.

What geographic markets are most important?

North America and Europe remain important because of high pharmaceutical quality requirements and established branded suppliers. Asia-Pacific is the main volume-growth region because of generic-drug manufacturing, expanding domestic pharmaceutical production, and increasing use of modern topical and oral delivery systems.

Geographic differences include:

• United States: FDA IID precedent, USP-NF compliance, customer audits
• European Union: Ph. Eur. compliance, excipient GMP expectations, supplier qualification
• India: strong generic manufacturing base and growing local excipient capacity
• China: expanding domestic supply and export capability
• Latin America: import dependence in several markets and sensitivity to landed cost

Supply-chain diversification is becoming more important as drug manufacturers seek qualified secondary sources. The qualification burden limits rapid replacement of established suppliers.

Key Takeaways

• Carbomer Homopolymer Type C is a mature, pharmaceutical-grade crosslinked polyacrylic acid excipient.
• No reliable public market size or standalone revenue series exists for the Type C category.
• Demand is supported by topical, ophthalmic, oral controlled-release, veterinary, and consumer-health applications.
• Lubrizol is a leading branded supplier, while regional manufacturers are increasing price competition.
• Core composition patents are mature; current defensibility rests on grade consistency, manufacturing know-how, regulatory documentation, and customer qualification.
• Carbomer has no standalone Orange Book listing, FDA exclusivity period, or Paragraph IV pathway.
• Patent risk arises primarily from finished drug formulations, controlled-release systems, ophthalmic products, and methods of use.
• The financial outlook is stable to moderately positive, with better margins for qualified pharmaceutical grades than for commodity carbomer.
• Generic-entry risk is highest for conventional topical products and lower for complex modified-release and ophthalmic systems.
• The strongest commercial moat is validated performance and supply reliability, not basic polymer patent protection.

FAQs About Carbomer Homopolymer Type C

Is Carbomer Homopolymer Type C the same as Carbopol?

No. Carbopol is a branded product family, while Carbomer Homopolymer Type C is a pharmacopeial classification. A particular Carbopol grade may correspond to a Type C designation, but the product specification must be verified against the supplier’s current technical and compendial documentation.

Is Carbomer Homopolymer Type C safe in pharmaceutical products?

Safety depends on grade, concentration, route of administration, impurity controls, and the finished formulation. Pharmaceutical use requires compliance with applicable specifications and evaluation within the drug product’s regulatory submission.

Can a pharmaceutical manufacturer switch carbomer suppliers without a new drug application?

A supplier change may be possible, but it can require comparability testing, stability studies, process assessment, and regulatory reporting. The filing requirement depends on the dosage form, the significance of the change, and the approved product’s regulatory commitments.

Does Carbomer Homopolymer Type C qualify as a high-value excipient?

It is a specialty excipient when sold in validated pharmaceutical grades. Its value is higher than that of industrial carbomer because of compendial testing, quality systems, regulatory support, and formulation qualification. It remains less differentiated than many novel excipients.

Are carbomer-containing ophthalmic products difficult for generics to copy?

They can be. Generic developers must match sterility, viscosity, drop formation, ocular residence time, preservative performance, container compatibility, and clinical or in vitro performance requirements. These factors can create meaningful development and approval barriers.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugsatfda
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/guidance-compliance-regulatory-information
4. United States Pharmacopeia. (2024). USP-NF: Carbomer monograph. United States Pharmacopeial Convention.
5. Lubrizol Advanced Materials. (n.d.). Carbopol pharmaceutical polymers: Technical and regulatory information. https://www.lubrizol.com
6. International Pharmaceutical Excipients Council. (2017). The IPEC-PQG good manufacturing practices guide for pharmaceutical excipients. IPEC Federation.
7. Ashland Global Holdings Inc. (2023). Annual report. https://investor.ashland.com